The National Heart, Lung, and Blood Institute (NHLBI) has awarded Albert Einstein College of Medicine a $455,826 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a double-blind, randomized, placebo-controlled trial examining the effects of chronic sildenafil administration on vascular remodeling in patients with left ventricular assist devices (LVADs). The study aims to determine if sildenafil can reduce vascular remodeling and related adverse events, such as stroke and bleeding, that often occur during prolonged LVAD support. The grant period runs from January 1, 2025 to December 31, 2029. The research team at Albert Einstein College of Medicine will assess outcomes including aortic stiffness, carotid distensibility, angiodysplasia formation, and endothelial dysfunction to evaluate the impact of sildenafil on vascular remodeling in this high-risk patient population.